ArticleJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine2026
The Clinical Significance of Fetal Intra-Abdominal Umbilical Vein Varix: A Comparative Study.
Article in Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo clarify the clinical significance and optimal management of fetal intra-abdominal umbilical vein varix (FIUVV).
methodsA retrospective study comparing composite asphyxia-related adverse outcomes including stillbirth, cesarean delivery due to non-reassuring fetal heart rate (CD NRFHR), Apgar <7, Cord pH <7, neonatal intensive care unit admission, mechanical ventilation, seizures, asphyxia, and hypoxic ischemic encephalopathy, as well as rates of small for gestational age (SGA) and congenital anomalies, between FIUVV singletons and the general population born at a single center. A subgroup analysis included FIUVV singletons and controls delivering ≥39 weeks.
resultsCompared to controls (99,715), FIUVV subjects (142) had more congenital anomalies (15.5% versus 0.84%, P < .01) and SGA (9.9% versus 5.4%, P = .02). There were no stillbirths among FIUVV. There were similar rates of CD NRFHR and asphyxia-related composite adverse outcomes between the study and control groups (4.2% versus 4.4%, P = .9; 7.7% versus 8.7%, P = .7) including the subgroup delivering ≥39 weeks (12.5% versus 4.6%, P = .06; 12.5% versus 5.7%, P = .09).
conclusionsFIUVV does not appear to increase asphyxia-related adverse outcomes. Targeted anomaly scan and growth assessment are recommended. There is no evidence to support labor induction before 39 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.